← Back to screener

VERTEX PHARMACEUTICALS INC / MA VRTX

Rank #955 · Nasdaq · $141.8B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
55.5
P/E
39.2
P/B
10.20
ROE
26.0%
Op. Margin
38.8%
Debt Ratio
44%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Weak

P/E 39.2x, P/B 10.20x. Ranks in the top 64% of the universe.

Profitability ★★★★☆
Excellent

ROE 26.0%. Ranks in the top 11% of the universe.

Safety ★★★★☆
Good

Debt ratio 44%. Ranks in the top 22% of the universe. Under 100% is generally considered a safe level.

Growth ★★★☆☆
Good

Revenue growth of 10.5% year over year. Ranks in the top 34% of the universe.

Profitability is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011$0.1B$-0.6B$-0.6B$0.5B-602.6242
2012$0.1B$-0.7B$-0.8B$0.8B-485.5157
2013$1.4B$0.1B$0.0B$1.0B8.1153
2014$1.5B$0.0B$-0.1B$1.4B3.171
2015$1.2B$-0.6B$-0.4B$1.1B-50.3115
2016$0.6B$-0.7B$-0.7B$0.9B-119.3149
2017$1.0B$-0.5B$-0.6B$1.2B-45.2135
2018$1.7B$0.0B$-0.1B$2.0B0.674
2019$2.5B$0.1B$0.3B$1.3B5.0135
2020$3.0B$0.6B$2.1B$2.0B20.8109
2021$4.2B$1.2B$1.2B$4.4B28.869
2022$6.2B$2.9B$2.7B$6.1B46.055
2023$7.6B$2.8B$2.3B$8.7B36.749
2024$8.9B$4.3B$3.3B$10.1B48.251
2025$9.9B$3.8B$3.6B$13.9B38.844

← See the full screener